Table 3. Association between Age-Related Macular Degeneration and Exposure according to Cumulative Duration.

Exposure	Cases* (n=2330)	Controls* (n=23278)	Crude OR (95% CI)	Adjusted ORs† (95% CI)
None	551 (23.7)	6900 (29.6)	1.00 (Reference)	1.00 (Reference)
Statins only
<90 days	33 (1.4)	268 (1.2)	1.56 (1.07–2.26)	1.30 (0.90–1.90)
90–299 days	77 (3.3)	877 (3.8)	1.11 (0.87–1.43)	0.95 (0.74–1.22)
≥300 days	100 (4.3)	864 (3.7)	1.47 (1.17–1.84)	1.22 (0.97–1.53)
Metformin only
<90 days	14 (0.6)	109 (0.5)	1.62 (0.92–2.85)	1.35 (0.76–2.39)
90–299 days	45 (1.9)	333 (1.4)	1.71 (1.24–2.36)	1.50 (1.07–2.09)
≥300 days	52 (2.2)	620 (2.7)	1.07 (0.79–1.43)	0.93 (0.68–1.26)
ACE inhibitors only
<90 days	0 (0.0)	22 (0.1)	N/A	N/A
90–299 days	12 (0.5)	128 (0.6)	1.19 (0.65–2.17)	1.18 (0.64–2.15)
300 days	16 (0.7)	217 (0.9)	0.94 (0.56–1.57)	0.87 (0.52–1.45)
ARBs only
<90 days	39 (1.7)	384 (1.7)	1.27 (0.90–1.78)	1.07 (0.76–1.52)
90–299 days	158 (6.8)	1378 (5.9)	1.45 (1.20–1.74)	1.35 (1.11–1.64)
≥300 days	259 (11.1)	2557 (11.0)	1.28 (1.10–1.50)	1.16 (0.98–1.36)
All combinations
<90 days	19 (0.8)	166 (0.7)	1.44 (0.89–2.33)	1.31 (0.80–2.13)
90–299 days	249 (10.7)	2274 (9.8)	1.39 (1.19–1.63)	1.23 (1.04–1.47)
≥300 days	706 (30.3)	6181 (26.6)	1.46 (1.29–1.64)	1.20 (1.05–1.38)

OR, odds ratio; CI, confidence interval; ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; N/A, not applicable.

Variables are presented as a number (percentage) unless otherwise noticed.

^*Cases and controls are matched by age, sex, cohort entry date, and follow-up duration; ^†Adjusted for income level, Charlson comorbidity index, the number of prescriptions, cerebrovascular disease history, complicated or uncomplicated diabetes, hyperlipidemia, hypertension and peripheral vascular disease, and the use of alpha-blockers, alpha-glucosidase, aspirin, beta-blockers, calcium channel blockers, diuretics, meglitinide, sulfonylurea, or thiazolidinedione.